AMBRISENTAN AND ITS ROLE IN THE MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION

Lain M. Maclntyre, Neeraj Dhaun, Jane Goddard, David J. Webb

Research output: Contribution to journalArticlepeer-review

Abstract

Ambrisentan is the second selective endothelin-A receptor antagonist to be licensed in Europe, and the first in the United States, for the management of pulmonary arterial hypertension (PAH). It has been shown to be clinically effective in improving exercise tolerance and functional class. Furthermore, ambrisentan is well tolerated and associated with low rates of liver toxicity and minimal interactions with other medicines commonly used to treat PAH. Overall, current data support a role for ambrisentan in the management of PAH. However, the results of longer-term follow-up studies are still required to fully assess efficacy and safety.

Original languageEnglish
Pages (from-to)875-885
Number of pages11
JournalDrugs of today
Volume44
Issue number12
DOIs
Publication statusPublished - Dec 2008

Cite this